Edition:
United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

20.00USD
14 Jun 2019
Change (% chg)

$-0.22 (-1.09%)
Prev Close
$20.22
Open
$20.21
Day's High
$20.51
Day's Low
$19.98
Volume
143,366
Avg. Vol
186,601
52-wk High
$36.12
52-wk Low
$19.27

Dallas, Jayson 

Dr. Jayson Dallas is appointed as President, Chief Executive Officer, Director of the company effective as of June 19, 2018. He joins the Company from Ultragenyx Pharmaceutical Inc., a public biopharmaceutical company, where he served as Executive Vice President since January 2016 and Chief Commercial Officer since August 2015. Between August 2015 and January 2016, he also served as Senior Vice President of Ultragenyx. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a public healthcare company, in the United Kingdom from July 2012 to July 2015. Prior to this, he held two different positions at Genentech, a public pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology from May 2010 to June 2012. Prior to joining Genentech, Dr. Dallas worked at Novartis and Pharmacia in the U.S. and previously at Roche in Switzerland. Dr. Dallas has also served as a board member of Arena Pharmaceuticals Inc. since February 2017. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --